# Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

> **NCT04180813** · — · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 85 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT04180813
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-04
- **Primary completion:** 2021-07-11
- **Final completion:** 2021-07-11
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Study enrollment did not meet expectation.
- **Last updated:** 2022-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180813

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180813, "Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04180813. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*